Agricultural biotechnology company Micropep Technologies has submitted regulatory dossiers for its flagship peptide-based biofungicide Promisin in the United States and the European Union, marking a major step toward commercializing a new class of sustainable crop protection products. The latest submissions extend Micropep's regulatory reach beyond earlier filings in Brazil and Paraguay, positioning the company across three of the world's most influential agricultural regions as it seeks global approval for its lead crop protection technology.
While regulatory applications in Latin America focus on soybean diseases, the U.S. and EU submissions target fungal diseases affecting grapevine and potato, reflecting the product's expanding application across both broad-acre and high-value crops. Promisin is the first commercial candidate developed through Micropep's proprietary Krisalix discovery platform, which uses peptide-based technologies to create next-generation biological crop protection products. The company says the biofungicide combines a novel peptide-based mode of action with commercial-scale performance and production economics suitable for widespread agricultural adoption.
The regulatory milestone follows more than three years of product development and over 200 field trials conducted across North America, Europe and Latin America. According to the company, Promisin has consistently demonstrated strong control of major fungal diseases while remaining compatible with existing crop protection programs. "The completion of our U.S. and EU regulatory submissions represents a defining milestone for Micropep and validates years of scientific innovation and field development of Promisin," said Dr. Kevin Leiner, Chief Regulatory Officer at Micropep. He added that the company looks forward to working with regulatory authorities as it advances the review process and prepares to introduce its first peptide-based biofungicide to growers seeking innovative and sustainable disease management solutions.
Micropep has positioned Promisin as a response to several structural challenges facing global agriculture, including rising fungicide resistance, evolving regulatory standards and increasing demand for environmentally responsible crop protection technologies. Among its key features, the company highlights broad-spectrum activity against fungal pathogens, a novel peptide-based mode of action, compatibility with resistance management programs, suitability for tank-mixing and rotational use, a favorable environmental and safety profile with no residue concerns, and production economics designed for large-scale commercial agriculture.
Beyond Promisin, Micropep is continuing to expand its innovation pipeline through the Krisalix platform, with peptide candidates under development targeting fungal diseases, insect pests and invasive weeds. "Promisin shows that peptide-based solutions can deliver the performance, scalability, and economics required for broad agricultural adoption, opening the door to a new generation of products for growers worldwide," said Georg Goeres, Chief Executive Officer of Micropep. The regulatory submissions reinforce the growing momentum behind peptide-based biologicals as the crop protection industry accelerates investment in sustainable technologies capable of complementing or replacing conventional chemical pesticides.
